10 July 2008: Sarsia Life Science Fund AS, in which the chairman of the board of NorDiag ASA, Hans Hekland, is the CEO, has been allotted 5,000,000 new shares in NorDiag ASA at a price of NOK 2.00 in the rights issue of the company. In total, Sarsia Life Science Fund AS will own 11,210,661 shares in NorDiag ASA, which amounts to about 21% of the share capital.

Novel Diagnostics ASA, in which the chairman of the board of NorDiag ASA, Hans Hekland, is the chairman of the board, has been allotted 201,000 new shares in NorDiag ASA at a price of NOK 2.00 in the rights issue of the company. In total, Novel Diagnostics ASA will own 4,055,660 shares in NorDiag ASA, which amounts to about 7.6% of the share capital.

Biovekst AS, in which board member of NorDiag ASA, Ann-Kristin Hageløkken, is the CEO, has been allotted 442,000 new shares in NorDiag ASA at a price of NOK 2.00 in the rights issue of the company. In total, Biovekst AS will own 2 665 606 shares in NorDiag ASA, which amounts to about 4.9% of the share capital.

Read the Notice in Norwegian here